AstraZeneca and Daiichi Sankyo have withdrawn their marketing authorisation application in the European Union (EU) voluntarily, intended for datopotamab deruxtecan (Dato-DXd), to treat advanced ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug ... AstraZeneca and Daiichi’s ADC datopotamab deruxtecan (Dato-DXd) has the same mechanism as Trodelvy. But improvements in ...

Earlier this month, the FDA granted a Breakthrough Therapy designation to Dato-DXd for previously treated advanced EGFR-mutated NSCLC. Besides lung cancer, AstraZeneca and Daiichi Sankyo are also ...

AstraZeneca and Daiichi Sankyo have moved swiftly to file for FDA approval of a second indication for their TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), this time for ...

AstraZeneca, which is partnered with Daiichi Sankyo on the drug, has cited Dato-DXd as one of the products that will help it achieve its goal of nearly doubling its revenue to $80 billion by 2030.

Daiichi Sankyo has claimed approval in Japan, its home market, for TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd ... in other markets to AstraZeneca in 2020 ...

Dato-DXd is being jointly developed by AstraZeneca and Daiichi Sankyo. This marks the first BTD for Dato-DXd for any indication. Year to date, shares of AstraZeneca have inched up 1.8% compared ...

With AstraZeneca and Daiichi Sankyo pursuing a wide range of potential indications for Dato-DXd, there are still opportunities for the narrative to improve. Phase III results from the TB-02 study ...

A next-generation form of chemotherapy from AstraZeneca and Daiichi Sankyo has won Food and Drug ... Datroway, also called datopotamab deruxtecan, or Dato-DXd, was approved in Japan for a form ...

Daiichi Sankyo and AstraZeneca have initiated three Phase III clinical trials to evaluate the efficacy and safety of datopotamab deruxtecan (Dato-DXd)-based combinations in patients with advanced ...